SABSW

SAB Biotherapeutics, Inc. [SABSW] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

SABSW Stock Summary

Top 10 Correlated ETFs

SABSW

Top 10 Correlated Stocks

SABSW

In the News

SABSW Financial details

Company Rating
-
Market Cap
41.42M
Income
-42.24M
Revenue
2.24M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
57
Optionable
No
Shortable
Yes
Earnings
31 Mar 2023
P/E
-11.42
Forward P/E
-
PEG
-1.47
P/S
0.3
P/B
20.4
P/C
-
P/FCF
0.87
Quick Ratio
0.26
Current Ratio
0.34
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-7.66
EPS next Y
-
EPS next Q
-
EPS this Y
77.26%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
103.3%
Revenue last 5Y
-8.24%
Revenue Q/Q
-75.93%
EPS Q/Q
297.94%
-
-
-
-
SMA20
-75%
SMA50
-50%
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-96%
ROE
-121%
ROC
-1.41%
Gross Margin
100%
Oper. Margin
-139%
Profit Margin
-140%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.03-0.0304
52W High
-
52W Low
-
RSI
39.47
Rel Volume
-
Avg Volume
-
Volume
6.72K
Perf Week
-12.33%
Perf Month
-69.06%
Perf Quarter
-
Perf Half Y
-12.33%
-
-
-
-
Beta
0.801
-
-
Volatility
0%, 0.04%
Prev Close
-12.33%
Price
0.0263
Change
-12.62%

Something similar

Top by Market Cap
M&M.NS
META
AVGO
BRH.DE
TL0.DE
Top Correlated ETFs
ADOT.SW
3097.HK
3175.HK
3LAM.PA
GBEU.MI
Top Correlated Stocks
2KD.DE
0548.HK
2208.HK
1965.HK
VLHZ.ME
Similar Market Cap
KSC.DE
VALD.DE
E903.F
SLBEN.LS
JGGCU

Company Profile

Healthcare Biotechnology

SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. It offers SAB-142 anti-thymocyte globulin for Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV). SAB Biotherapeutics, Inc. was incorporated in 2014 and is based in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.